Gap junction activity in lens epithelial cells is regulated by PKC␥-mediated phosphorylation of Cx43. PKC␥ activity is stimulated by growth factor-regulated increases in the synthesis of diacylglycerol but is inhibited by cytosolic docking proteins such as 14-3-3. Here we have identified two sites on the PKC␥-C1B domain that are responsible for its interaction with 14-3-3⑀. Two sites, C1B1 (residues 101-112) and C1B5 (residues 141-151), are located within the C1 domain of PKC␥. C1B1 and/or C1B5 synthetic peptides can directly compete for the binding of 14-3-3⑀, resulting in the release of endogenous cellular PKC␥ from 14-3-3⑀, in vivo or in vitro, in activation of PKC␥ enzyme activity, phosphorylation of PKC␥, in the subsequent translocation of PKC␥ to the membrane, and in inhibition of gap junction activity. Gap junction activity was decreased by at least 5-fold in cells treated with C1B1 or C1B5 peptides when compared with a control. 100 M of C1B1 or C1B5 peptides also caused a 10-or 4-fold decrease of Cx43 plaque formation compared with control cells. The uptake of these synthetic peptides into cells was verified by using high pressure liquid chromatography and matrix-assisted laser desorption ionization time-of-flight-mass spectrometry. We have demonstrated that the activity and localization of PKC␥ are regulated by its binding to 14-3-3⑀ at the C1B domain of PKC␥. Synthetic peptides corresponding to these regions of PKC␥ successfully competed for the binding of 14-3-3⑀ to endogenous PKC␥, resulting in inhibition of gap junction activity. This demonstrates that synthetic peptides can be used to exogenously regulate gap junctions.